Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients

Authors: Dechao Feng, Jie Wang, Xu Shi, Dengxiong Li, Wuran Wei, Ping Han

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Prostate cancer (PCa) is usually considered as cold tumor. Malignancy is associated with cell mechanic changes that contribute to extensive cell deformation required for metastatic dissemination. Thus, we established stiff and soft tumor subtypes for PCa patients from perspective of membrane tension.

Methods

Nonnegative matrix factorization algorithm was used to identify molecular subtypes. We completed analyses using software R 3.6.3 and its suitable packages.

Results

We constructed stiff and soft tumor subtypes using eight membrane tension-related genes through lasso regression and nonnegative matrix factorization analyses. We found that patients in stiff subtype were more prone to biochemical recurrence than those in soft subtype (HR 16.18; p < 0.001), which was externally validated in other three cohorts. The top ten mutation genes between stiff and soft subtypes were DNAH, NYNRIN, PTCHD4, WNK1, ARFGEF1, HRAS, ARHGEF2, MYOM1, ITGB6 and CPS1. E2F targets, base excision repair and notch signaling pathway were highly enriched in stiff subtype. Stiff subtype had significantly higher TMB and T cells follicular helper levels than soft subtype, as well as CTLA4, CD276, CD47 and TNFRSF25.

Conclusions

From the perspective of cell membrane tension, we found that stiff and soft tumor subtypes were closely associated with BCR-free survival for PCa patients, which might be important for the future research in the field of PCa.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49.
2.
3.
Shih KW, Chen WC, Chang CH, Tai TE, Wu JC, Huang AC, et al. Non-muscular invasive bladder cancer: re-envisioning therapeutic journey from traditional to regenerative interventions. Aging Dis. 2021;12(3):868–85.PubMedPubMedCentralCrossRef
4.
5.
Feng D, Shi X, You J, Xiong Q, Zhu W, Wei Q, et al. A cellular senescence-related gene prognostic index for biochemical recurrence and drug resistance in patients with prostate cancer. Am J Cancer Res. 2022;12(8):3811–28.PubMedPubMedCentral
6.
7.
Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.PubMedCrossRef
8.
Feng D, Li D, Shi X, Xiong Q, Zhang F, Wei Q, et al. A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer. J Transl Med. 2022;20(1):252.PubMedPubMedCentralCrossRef
9.
Feng D, Shi X, Zhu W, Zhang F, Li D, Han P, et al. A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. Exp Hematol Oncol. 2022;11(1):55.PubMedPubMedCentralCrossRef
10.
Feng D, Zhang F, Liu L, Xiong Q, Xu H, Wei W, et al. SKA3 serves as a biomarker for poor prognosis in kidney renal papillary cell carcinoma. Int J Gen Med. 2021;14:8591–602.PubMedPubMedCentralCrossRef
11.
Feng D, Zhu W, Shi X, Xiong Q, Li D, Wei W, et al. Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer. Exp Hematol Oncol. 2022;11(1):76.PubMedPubMedCentralCrossRef
12.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, et al. A ferroptosis-related gene prognostic index associated with biochemical recurrence and radiation resistance for patients with prostate cancer undergoing radical radiotherapy. Front Cell Dev Biol. 2022;10: 803766.PubMedPubMedCentralCrossRef
13.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Mitochondria dysfunction-mediated molecular subtypes and gene prognostic index for prostate cancer patients undergoing radical prostatectomy or radiotherapy. Front Oncol. 2022;12: 858479.PubMedPubMedCentralCrossRef
14.
Feng D, Xiong Q, Zhang F, Shi X, Xu H, Wei W, et al. Identification of a novel nomogram to predict progression based on the circadian clock and insights into the tumor immune microenvironment in prostate cancer. Front Immunol. 2022;13: 777724.PubMedPubMedCentralCrossRef
15.
Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.PubMedCrossRef
16.
Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol. 2013;10(1):38–48.PubMedCrossRef
17.
Feng D, Shi X, Xiong Q, Zhang F, Li D, Yang L. A gene prognostic index associated with epithelial-mesenchymal transition predicting biochemical recurrence and tumor chemoresistance for prostate cancer. Front Oncol. 2021;11: 805571.PubMedCrossRef
18.
Feng D, Zhang F, Li D, Shi X, Xiong Q, Wei Q, et al. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer. Immunology. 2022;166(2):197–209.PubMedCrossRef
19.
Feng D, Zhu W, Shi X, Wang Z, Wei W, Wei Q, et al. Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy. Exp Hematol Oncol. 2023;12(1):8.PubMedPubMedCentralCrossRef
20.
Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Energy metabolism-related gene prognostic index predicts biochemical recurrence for patients with prostate cancer undergoing radical prostatectomy. Front Immunol. 2022;13: 839362.PubMedPubMedCentralCrossRef
21.
Hu D, Cao Q, Tong M, Ji C, Li Z, Huang W, et al. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer. BMC Med Genomics. 2022;15(1):24.PubMedPubMedCentralCrossRef
22.
Ke Z-B, You Q, Chen J-Y, Sun J-B, Xue Y-T, Zhuang R-B, et al. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients. Comput Biol Med. 2022;2022–07(146): 105711.CrossRef
23.
Ferro M, de Cobelli O, Musi G, Del Giudice F, Carrieri G, Busetto GM, et al. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol. 2022;14:17562872221109020.PubMedPubMedCentralCrossRef
24.
Massanova M, Robertson S, Barone B, Dutto L, Caputo VF, Bhatt JR, et al. The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study. Urol Int. 2021;105(9–10):804–10.PubMedCrossRef
25.
Pontes B, Monzo P, Gauthier NC. Membrane tension: a challenging but universal physical parameter in cell biology. Semin Cell Dev Biol. 2017;2017–11(71):30–41.CrossRef
26.
Sung S-Y, Hsieh C-L, Wu D, Chung LWK, Johnstone PAS. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.PubMedCrossRef
27.
Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571–82.PubMedCrossRef
28.
Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, et al. Tumor mechanics and metabolic dysfunction. Free Radical Biol Med. 2015;2015–02(79):269–80.CrossRef
29.
Castaño Z, Tracy K, McAllister SS. The tumor macroenvironment and systemic regulation of breast cancer progression. Int J Dev Biol. 2011;55(7–9):889–97.PubMedCrossRef
30.
Tsujita K, Satow R, Asada S, Nakamura Y, Arnes L, Sako K, et al. Homeostatic membrane tension constrains cancer cell dissemination by counteracting BAR protein assembly. Nat Commun. 2021;12(1):5930.PubMedPubMedCentralCrossRef
31.
Simunovic M, Evergren E, Callan-Jones A, Bassereau P. Curving cells inside and out: roles of BAR domain proteins in membrane shaping and its cellular implications. Annu Rev Cell Dev Biol. 2019;35:111–29.PubMedCrossRef
32.
Park JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, et al. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature. 2020;578(7796):621–6.PubMedPubMedCentralCrossRef
33.
Hamill OP, Martinac B. Molecular basis of mechanotransduction in living cells. Physiol Rev. 2001;81(2):685–740.PubMedCrossRef
34.
Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241–54.PubMedCrossRef
35.
Mortensen MM, Høyer S, Lynnerup A-S, Ørntoft TF, Sørensen KD, Borre M, et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015;5:16018.PubMedPubMedCentralCrossRef
36.
Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, et al. Validation of a metastatic assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29(1):215–22.PubMedCrossRef
37.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
38.
39.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
40.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 30. Bioinformatics. 2011;27(12):1739–40.PubMedPubMedCentralCrossRef
41.
42.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-54 e15.PubMedPubMedCentralCrossRef
43.
44.
45.
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.PubMedPubMedCentralCrossRef
46.
Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12: 687975.PubMedPubMedCentralCrossRef
47.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.PubMedPubMedCentralCrossRef
48.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.PubMedPubMedCentralCrossRef
49.
50.
Bastatas L, Martinez-Marin D, Matthews J, Hashem J, Lee YJ, Sennoune S, et al. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. Biochem Biophys Acta. 2012;1820(7):1111–20.PubMedCrossRef
51.
Lekka M, Gil D, Pogoda K, Dulińska-Litewka J, Jach R, Gostek J, et al. Cancer cell detection in tissue sections using AFM. Arch Biochem Biophys. 2012;518(2):151–6.PubMedCrossRef
52.
53.
Liu N, Du P, Xiao X, Liu Y, Peng Y, Yang C, et al. Microfluidic-based mechanical phenotyping of androgen-sensitive and non-sensitive prostate cancer cells lines. Micromachines. 2019;10(9):E602.CrossRef
54.
Molter CW, Muszynski EF, Tao Y, Trivedi T, Clouvel A, Ehrlicher AJ. Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Front Cell Devel Biol. 2022;10:932510.CrossRef
55.
Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007;213(1):82–90.PubMedCrossRef
56.
Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res: An Official J Am Assoc Cancer Res. 1999;5(5):1063–71.
57.
Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559–71.PubMedCrossRef
58.
Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031–41.PubMedPubMedCentralCrossRef
59.
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474-89.e6.PubMedPubMedCentralCrossRef
60.
Guccini I, Revandkar A, D’Ambrosio M, Colucci M, Pasquini E, Mosole S, et al. Senescence reprogramming by timp1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021;39(1):68-82.e9.PubMedCrossRef
61.
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):E9739.CrossRef
62.
Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38–53.PubMedCrossRef
63.
Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, et al. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate. 2014;74(5):528–36.PubMedCrossRef
64.
Yamamoto H, Sutoh M, Hatakeyama S, Hashimoto Y, Yoneyama T, Koie T, et al. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J Urol. 2011;185(5):1930–8.PubMedCrossRef
65.
Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol (Northwood, London, England). 2018;35(5):71.CrossRef
66.
Yoon BK, Hwang N, Chun K-H, Lee Y, Duarte TPM, Kim J-W, et al. Sp1-induced FNBP1 drives rigorous 3D cell motility in EMT-type gastric cancer cells. Int J Mol Sci. 2021;22(13):6784.PubMedPubMedCentralCrossRef
67.
Wang Z, Tian Z, Song X, Zhang J. Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA LUAD and STAD. BMC immunol. 2022;23(1):1.PubMedPubMedCentralCrossRef
68.
Son J, Park MS, Park I, Lee H-K, Lee S-H, Kang B, et al. Pick1 modulates ephrinB1-induced junctional disassembly through an association with ephrinB1. Biochem Biophys Res Commun. 2014;450(1):659–65.PubMedCrossRef
69.
Dai Y, Ren D, Yang Q, Cui Y, Guo W, Lai Y, et al. The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone. Br J Cancer. 2017;117(5):685–94.PubMedPubMedCentralCrossRef
70.
Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9(1):70–5.PubMedCrossRef
71.
Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef
72.
73.
Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, et al. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2004;10(2):572–80.CrossRef
74.
Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef
75.
Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed
76.
Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011;22(24):4750–64.PubMedPubMedCentralCrossRef
77.
Wang C-C, Liau J-Y, Lu Y-S, Chen J-W, Yao Y-T, Lien H-C. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology. 2012;61(1):78–87.PubMedCrossRef
78.
Gao X, Liu Q, Chen X, Chen S, Yang J, Liu Q, et al. Screening of tumor grade-related mRNAs and lncRNAs for esophagus squamous cell carcinoma. J Clin Lab Anal. 2021;35(6):e23797.PubMedPubMedCentralCrossRef
79.
Funato Y, Terabayashi T, Suenaga N, Seiki M, Takenawa T, Miki H. IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness. Cancer Res. 2004;64(15):5237–44.PubMedCrossRef
80.
Cheng M, Jiang Y, Yang H, Zhao D, Li L, Liu X. FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway. Am J Cancer Res. 2020;10(2):403–23.PubMedPubMedCentral
81.
82.
Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, et al. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer. JAMA Oncol. 2016;2(4):471–80.PubMedPubMedCentralCrossRef
83.
Vasquez JL, Lai Y, Annamalai T, Jiang Z, Zhang M, Lei R, et al. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020;2020–01(168):241–50.CrossRef
84.
CGAR Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef
85.
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–51.PubMedPubMedCentralCrossRef
86.
87.
88.
Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (New York, NY). 1999;284(5415):770–6.CrossRef
89.
Kawaguchi K, Kaneko S. Notch signaling and liver cancer. Adv Exp Med Biol. 2021;2021(1287):69–80.CrossRef
90.
Shen Q, Reedijk M. Notch signaling and the breast cancer microenvironment. Adv Exp Med Biol. 2021;2021(1287):183–200.CrossRef
91.
Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal cancer. Cells. 2020;9(6):E1549.CrossRef
92.
Wang X-D, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol. 2006;290(1):66–80.PubMedCrossRef
93.
Villaronga MA, Bevan CL, Belandia B. Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets. 2008;8(7):566–80.PubMedCrossRef
94.
Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41–51.PubMedCrossRef
95.
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol: Official J Eur Soc Med Oncol. 2019;30(1):44–56.CrossRef
96.
Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–73.PubMedCrossRef
97.
Luo C, Chen J, Chen L. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Int Immunopharmacol. 2020;2020–09(86): 106709.CrossRef
98.
Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;2020(1248):7–32.CrossRef
99.
Kern R, Panis C. CTLA-4 expression and its clinical significance in breast cancer. Arch Immunol Et Ther Exp. 2021;69(1):16.CrossRef
100.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRef
101.
Liu J-N, Kong X-S, Huang T, Wang R, Li W, Chen Q-F. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study. Front Immunol. 2020;2020(11):2048.CrossRef
102.
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–79.PubMedCrossRef
103.
104.
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7–H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67(16):7893–900.PubMedCrossRef
105.
Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7–H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Dis. 2017;20(1):28–35.CrossRef
106.
Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol: Official J Japanese Urol Assoc. 2012;19(8):749–56.CrossRef
107.
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7–H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104(49):19458–63.PubMedPubMedCentralCrossRef
108.
Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, et al. Tumor B7–H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):767–74.PubMedCrossRef
Metadata
Title
Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients
Authors
Dechao Feng
Jie Wang
Xu Shi
Dengxiong Li
Wuran Wei
Ping Han
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01132-4

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy

Research

The burden of critical illness among adults in a Swedish region—a population-based point-prevalence study

Research

Risk factors analysis and survival prediction model establishment of patients with lung adenocarcinoma based on different pyroptosis-related gene subtypes

Review

Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis

Research

Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework

Research

Local YB-1, Epo, and EpoR concentrations in fractured bones: results from a porcine model of multiple trauma